HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology].

AbstractBACKGROUND AND OBJECTIVES:
Treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe cases, the use of immunoglobulin is not generally based on data from randomized controlled trials usually required for evidence-based medicine. Since the indications for the use of IVIg are rare, it is unlikely that such studies will be available in the foreseeable future. Because first-line use is limited by the high costs of IVIg, the first clinical guidelines on the use of IVIg in dermatological conditions were established in 2008 and renewed in 2011.
METHODS:
The European guidelines presented here were prepared by a panel of experts nominated by the European Dermatology Forum (EDF) and European Academy of Dermatology and Venereology (EADV). The guidelines were developed to update the indications for treatment currently considered effective and to summarize the evidence for the use of IVIg in dermatological autoimmune diseases and TEN.
RESULTS AND CONCLUSION:
The current guidelines represent consensual expert opinions and definitions on the use of IVIg reflecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in dermatological diseases.
AuthorsEva Hadaschik, Rüdiger Eming, Lars E French, Giampiero Girolomoni, Michael Hertl, Stephen Jolles, Sarolta Karpati, Kerstin Steinbrink, Georg Stingl, Beatrix Volc-Platzer, Detlef Zillikens, Alexander Enk
JournalDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete (Hautarzt) Vol. 71 Issue 7 Pg. 542-552 (Jul 2020) ISSN: 1432-1173 [Electronic] Germany
Vernacular TitleEuropäische Leitlinien (S1) für die Verwendung von hoch dosierten intravenösen Immunglobulinen in der Dermatologie.
PMID32435817 (Publication Type: Journal Article, Review)
Chemical References
  • Immunoglobulins, Intravenous
Topics
  • Autoimmune Diseases (diagnosis, drug therapy)
  • Dermatology (methods, standards)
  • Dose-Response Relationship, Drug
  • Europe
  • Humans
  • Immunoglobulins, Intravenous (administration & dosage, therapeutic use)
  • Practice Guidelines as Topic
  • Skin Diseases (diagnosis, drug therapy)
  • Stevens-Johnson Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: